NEW YORK (GenomeWeb) – Signal Genetics today priced its public offering of 3,214,285 shares of common stock at $2.80 per share. 

Gross proceeds from the offering are anticipated to be about $9 million and will go toward the clinical development of new products and services, expansion of the company's commercialization efforts, working capital, and general corporate purposes. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.